FibroBiologics
Growth Stage
The Future of Cell Therapy
Overview
Raised: $4,999,987
Total Commitments ($USD)
Platform
StartEngine
Start Date
01/31/2023
Close Date
05/01/2023
Min. Goal
$10,000
Max. Goal
$4,999,999
Min. Investment
$499
Security Type
Equity - Preferred
Series
Seed
SEC Filing Type
RegCF
Price Per Share
$1.69
Pre-Money Valuation
$252,568,627
Rolling Commitments ($USD)
Status
Active
Reporting Date
03/23/2023
Days Remaining
39
% of Min. Goal
50,001%
% of Max. Goal
100%
Likelihood of Max
Avg. Daily Raise
$98,039
# of Investors
713
Momentum
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2021
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2B
Margin
Medium
Capital Intensity
High
FibroBiologics, with a valuation of $252.6 million, is raising funds on StartEngine. It is a cell therapy biotech and pharmaceutical company with five product candidates in the pipeline. The product candidates of FibroBiologics target different medical areas, including degenerative disc disease, multiple sclerosis, wound healing, cancer, and extension of life applications. FibroBiologics has over 160 U.S. and international patents and may get approval for its first product in 2023. Peter O’Heeron founded FibroBiologics in April 2021. The current crowdfunding campaign has a minimum target of $9,999.73 and a maximum target of $5 million. The campaign proceeds will be used for research and development and administration expenses.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-1,582,000 |
$-1,169,000 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$407,000 |
$0 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$468,000 |
$0 |
|
Short-Term Debt |
$1,758,000 |
$0 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$1,758,000 |
$0 |
Financials as of: 01/31/2023
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Ratings 
Wall Street has Morningstar, S&P, and Bloomberg
The equity crowdfunding market has KingsCrowd.
Are you the founder of FibroBiologics? Create your account today to claim this raise page.